Please login to the form below

Not currently logged in

Teva launches study bursaries

Teva UK has launched a new study bursary scheme to tackle what it calls a 'demographic time-bomb' facing British-based pharmacy.
Teva UK has launched a new study bursary scheme to tackle what it calls a 'demographic time-bomb' facing British-based pharmacy. Pharmacists are getting older and selling-up creating a pressing need for new people to be recruited and trained, said Philippa Ward, communications and PR officer at the company.

Any home UK student already taking or offered a place on any full-time undergraduate course at a British academic institution can apply for the bursaries which will be awarded to potential pharmacy graduates who would otherwise struggle to cope financially. Teva already has initiatives in operation to support pharmacists in the changing healthcare environment but is looking to give its backing to future sector professionals.

Lynda Wilebore, Teva's HR director, said: "We are delighted to be able to introduce the student bursary scheme, which we hope will make an important contribution to the lives of under-privileged students in the UK."

"We are totally committed to pharmacy in the UK. This means we're not only interested in supporting the pharmacists of today, but also in ensuring the pharmacists of tomorrow get the best possible start," she concluded.

Wilebore explained that it is important to the interests of Teva, a UK generics manufacturer, that it has in place a community support programme that is relevant to its business.

Preference for the bursaries will be given to A-level students who are in receipt of education maintenance allowance or carers' allowance. The company will award 10 bursaries per year. Each one will be worth £500 per academic year of study and the deadline for the current round of applications is September 1, 2008.

14th May 2008


Featured jobs

Subscribe to our email news alerts


Add my company
Market Study Report

Market Study Report is a hub for market intelligence products and services. We streamline the purchase of your market research...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...